Regulatory News
Wednesday, November 30, 2016
BRIEF-Blueprint Medicines announces proof-of-concept data from Phase 1 clinical trial of BLU-285
* Blueprint Medicines announces proof-of-concept data from
Phase 1 clinical trial of BLU-285 in patients with advanced
gastrointestinal stromal tumors
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment